Compare Quest Diagnostics Inc (DGX) vs Trade Desk Inc (TTD) Price & Performance

Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.

The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.

The Trade Desk (TTD) trades at $12.09, down 67% year-to-date amid slowing revenue growth and increased competition. The stock shows bearish technical signals with mixed earnings performance - beating Q4 2025 and Q2 2026 estimates but missing Q1 2026. Despite strong profitability metrics including 76.87% gross margins and 15.44% ROE, the company faces headwinds from Amazon and other tech giants entering the ad-tech space, with recent workforce reductions signaling operational challenges.

While TTD maintains leadership in programmatic advertising with healthy cash flow generation, near-term outlook remains cautious due to competitive pressures and slowing growth. The stock trades at attractive valuation multiples (P/E 0.15, P/S 0.02) but requires clear catalysts to reverse the downward trend. Investors should weigh the company's strong market position against execution risks in a rapidly evolving digital advertising landscape.